Catal­ent switch­es CFO as 'pro­duc­tiv­i­ty is­sues' and un­ex­pect­ed costs hurt rev­enue — shares plum­met

Pro­duc­tiv­i­ty is­sues and high­er-than-ex­pect­ed costs at three of Catal­ent’s ma­jor man­u­fac­tur­ing plants — in­clud­ing one mak­ing gene ther­a­pies — are ex­pect­ed to hurt its fi­nan­cial re­sults for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER